Press Releases

08.22.2018

Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer

08.20.2018

Pfizer Invites Public To View And Listen To Webcast Of August 27 Conference Call With Analysts And Investors To Review Tafamidis Data Presentation At ESC Congress 2018

08.16.2018

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

08.08.2018

SANGAMO ANNOUNCES POSITIVE PRELIMINARY DATA FROM THE PHASE 1/2 ALTA STUDY EVALUATING SB-525 GENE THERAPY FOR HEMOPHILIA A

08.01.2018

XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis

07.31.2018

PFIZER REPORTS SECOND-QUARTER 2018 RESULTS

07.31.2018

Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)

07.24.2018

Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs

07.20.2018

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)

07.18.2018

Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

07.16.2018

Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy

07.13.2018

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)